These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27960617)

  • 1. Nuclear DNA replication and repair in parasites of the genus Leishmania: Exploiting differences to develop innovative therapeutic approaches.
    Uzcanga G; Lara E; Gutiérrez F; Beaty D; Beske T; Teran R; Navarro JC; Pasero P; Benítez W; Poveda A
    Crit Rev Microbiol; 2017 Mar; 43(2):156-177. PubMed ID: 27960617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors in potential drug development for Leishmaniasis.
    Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
    Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current approaches to discover marine antileishmanial natural products.
    Tempone AG; Martins de Oliveira C; Berlinck RG
    Planta Med; 2011 Apr; 77(6):572-85. PubMed ID: 21243582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional Versus Natural Alternative Treatments for Leishmaniasis: A Review.
    Passero LFD; Cruz LA; Santos-Gomes G; Rodrigues E; Laurenti MD; Lago JHG
    Curr Top Med Chem; 2018; 18(15):1275-1286. PubMed ID: 30277153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation by chemotherapeutic agents against Leishmaniasis.
    Saha P; Mukhopadhyay D; Chatterjee M
    Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania spp.: proficiency of drug-resistant parasites.
    Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
    Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug delivery: lessons to be learnt from Leishmania studies.
    Shaw CD; Carter KC
    Nanomedicine (Lond); 2014 Jul; 9(10):1531-44. PubMed ID: 25253500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of leishmaniasis: a review and assessment of recent research.
    Elmahallawy EK; Agil A
    Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
    Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
    Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity.
    Sharlow ER; Leimgruber S; Murray S; Lira A; Sciotti RJ; Hickman M; Hudson T; Leed S; Caridha D; Barrios AM; Close D; Grögl M; Lazo JS
    ACS Chem Biol; 2014 Mar; 9(3):663-72. PubMed ID: 24328400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.
    Chandra S; Ruhela D; Deb A; Vishwakarma RA
    Expert Opin Ther Targets; 2010 Jul; 14(7):739-57. PubMed ID: 20536412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?
    Ennes-Vidal V; Menna-Barreto RF; Branquinha MH; Dos Santos AL; D'Avila-Levy CM
    Parasitology; 2017 Feb; 144(2):117-123. PubMed ID: 27869056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
    Benaim B; Garcia CR
    Trop Biomed; 2011 Dec; 28(3):471-81. PubMed ID: 22433874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches from nanomedicine for treating leishmaniasis.
    Gutiérrez V; Seabra AB; Reguera RM; Khandare J; Calderón M
    Chem Soc Rev; 2016 Jan; 45(1):152-68. PubMed ID: 26487097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmaniasis: efflux pumps and chemoresistance.
    Leandro C; Campino L
    Int J Antimicrob Agents; 2003 Sep; 22(3):352-7. PubMed ID: 13678842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
    Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
    Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent patents in the treatment and prevention of leishmaniasis.
    Shahid SK
    Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A non-commercial approach for the generation of transgenic Leishmania tarentolae and its application in antileishmanial drug discovery.
    Pineda T; Valencia Y; Flórez MF; Pulido SA; Vélez ID; Robledo SM
    Parasitology; 2016 Aug; 143(9):1133-42. PubMed ID: 27174193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review.
    Cruz AK; de Toledo JS; Falade M; Terrão MC; Kamchonwongpaisan S; Kyle DE; Uthaipibull C
    Curr Drug Targets; 2009 Mar; 10(3):178-92. PubMed ID: 19275555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.